The CRC Digest

Curated CRC research — accessible, accurate, actionable

Wednesday, April 08, 2026

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◇ CXCR4 overexpression may predict immune checkpoint response in metastatic CRC

  Analysis of 15,026 colorectal cancer samples found that CXCR4 mRNA overexpression is associated with poor survival and may help identify which patients with metastatic disease could benefit from immune checkpoint inhibitors, potentially expanding treatment options beyond the current dMMR-only eligibility. (BMJ Oncology)

• ▸ Triple therapy shows limited benefit in RAS-mutant metastatic CRC trial

  The Phase I/II RASTRIC trial tested binimetinib, lapatinib, and vinorelbine in 40 patients with RAS-mutant metastatic colorectal cancer, finding the combination was safe but showed limited efficacy in this hard-to-treat patient population. (British Journal of Cancer)

• ◇ Targeting HIF-1α triggers ferroptosis in treatment-resistant MSS colorectal cancer

  Researchers found that blocking HIF-1α can induce ferroptosis (a form of cell death) and boost antitumor immunity in microsatellite stable CRC, offering a potential new approach for the majority of colorectal cancers that don't respond to immunotherapy. (Redox Biology)

• ▪ Long-term FIT screening data shows sustained detection rates over seven rounds

  Analysis of seven rounds of biennial FIT-based colorectal cancer screening found that adherent participants maintained consistent cancer detection rates, with positive predictive values and detection rates remaining stable over 14 years of screening. (Gut)

• ♥ Mild to moderate frailty doesn't affect long-term quality of life after colon cancer surgery

  A study of older adults found that those with mild to moderate frailty at diagnosis experienced similar quality of life, daily functioning, and treatment satisfaction one year after colon cancer surgery compared to non-frail patients. (Colorectal Disease)

These findings highlight ongoing efforts to expand treatment options, improve screening effectiveness, and better understand who benefits most from emerging therapies.